Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received May 9, 2002
- Accepted after revision August 15, 2002
- Published online January 1, 2003.
Copyright & Usage
Copyright © American Society of Neuroradiology
Author Information
- Marco Rovarisa,
- Giancarlo Comib,
- David Ladkanic,
- Jerry S. Wolinskyd,
- Massimo Filippia and
- European/Canadian Glatiramer Acetate Study Group
- aNeuroimaging Research Unit, Department of Neuroscience, Scientific Institute and University Ospedale San Raffaele, Milan, Italy
- bClinical Trials Unit, Department of Neuroscience, Scientific Institute and University Ospedale San Raffaele, Milan, Italy
- cTEVA Pharmaceutical Industries, Petah Tiqva, Israel
- dUniversity of Texas-Houston, Health Science Center
- Address reprint requests to Dr Massimo Filippi, Neuroimaging Research Unit, Department of Neuroscience, Scientific Institute and University Ospedale San Raffaele, via Olgettina 60, 20132 Milan, Italy
Altmetrics
Cited By...
In this issue
Jump to section
Related Articles
Cited By...
- One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis
- Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis
- New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate
- MRI as an outcome in multiple sclerosis clinical trials
- Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters
- A composite score to predict short-term disease activity in patients with relapsing-remitting MS
- MRI T2 lesion burden in multiple sclerosis: A plateauing relationship with clinical disability
- Predictors of relapse rate in MS clinical trials
- Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis
- Identifying and treating patients with suboptimal responses